Is CYTH or DIVO a better dividend investment in 2026?

CYTH currently yields 277.55% with a 5% 5-year dividend growth rate. DIVO yields 6.62% with 5% growth. The better choice depends on your goal: CYTH offers higher current income.

What is the dividend yield difference between CYTH and DIVO?

CYTH has a forward dividend yield of 277.55% ($2.00/share annually). DIVO yields 6.62% ($2.91/share annually). The yield gap is 270.93 percentage points.

Home › Compare › CYTH vs DIVO

CYTH vs DIVO: Dividend Comparison 2026

CYTH yields 277.55% · DIVO yields 6.62%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 CYTH wins by $903.12M in total portfolio value

INVESTMENT

TIME HORIZON10 years

CYTH

● Live price

277.55%

Share price

$0.72

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$903.15M

Annual income

$528,539,518.30

Full CYTH calculator →

DIVO

● Live price

6.62%

Share price

$44.00

Annual div

$2.91

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$31.0K

Annual income

$1,008.47

Full DIVO calculator →

Portfolio growth — CYTH vs DIVO

📍 CYTH pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	CYTH	DIVO
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, CYTH + DIVO cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

CYTH pays

DIVO pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CYTH

Annual income on $10K today (after 15% tax)

$23,591.45/yr

After 10yr DRIP, annual income (after tax)

$449,258,590.56/yr

DIVO

Annual income on $10K today (after 15% tax)

$562.67/yr

After 10yr DRIP, annual income (after tax)

$857.20/yr

At 15% tax rate, CYTH beats the other by $449,257,733.36/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CYTH + DIVO for your $10,000?

CYTH: 50%DIVO: 50%

100% DIVO50/50100% CYTH

Portfolio after 10yr

$451.59M

Annual income

$264,270,263.39/yr

Blended yield

58.52%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on CYTH right now

CYTH

Analyst Ratings

Buy

Hold

Consensus: Hold

Price Target

$0.95

+31.8% upside vs current

Range: $0.95 — $0.95

Altman Z

-45.6

Piotroski

3/9

DIVO

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CYTH buys

DIVO buys

No recent congressional trades found for CYTH or DIVO in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricCYTHDIVO

Forward yield	277.55% ✓	6.62%
Annual dividend / share	$2.00	$2.91 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$903.15M ✓	$31.0K
Annual income after 10y	$528,539,518.30 ✓	$1,008.47
Total dividends collected	$864.60M ✓	$8.4K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: CYTH vs DIVO ($10,000, DRIP)

Year	CYTH Portfolio	CYTH Income/yr	DIVO Portfolio	DIVO Income/yr	Gap
1← crossover	$38,455	$27,754.65	$11,362	$661.96	+$27.1K → CYTH
2	$140,894	$99,747.22	$12,860	$702.91	+$128.0K → CYTH
3	$492,311	$341,554.29	$14,504	$743.56	+$477.8K → CYTH
4	$1,642,154	$1,115,381.78	$16,303	$783.73	+$1.63M → CYTH
5	$5,234,184	$3,477,078.74	$18,268	$823.31	+$5.22M → CYTH
6	$15,958,335	$10,357,758.98	$20,408	$862.17	+$15.94M → CYTH
7	$46,588,915	$29,513,496.29	$22,737	$900.20	+$46.57M → CYTH
8	$130,375,354	$80,525,214.86	$25,266	$937.31	+$130.35M → CYTH
9	$350,102,914	$210,601,285.35	$28,008	$973.42	+$350.07M → CYTH
10	$903,149,637	$528,539,518.30	$30,977	$1,008.47	+$903.12M → CYTH

CYTH vs DIVO: Complete Analysis 2026

CYTH — Stock

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.

Full CYTH Calculator →

DIVO — ETF

DIVO is an ETF of high-quality large cap companies with a history of dividend and earnings growth, along with a tactical covered call* strategy on individual stocks. DIVO is strategically designed to offer high levels of total return on a risk-adjusted basis.

Full DIVO Calculator →

📬

Get this CYTH vs DIVO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CYTH vs SCHD CYTH vs JEPI CYTH vs O CYTH vs KO CYTH vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.